par Arsenijevic, Tatjana 
;Coulonval, Katia ;Raspé, Eric ;Demols, Anne ;Roger, Pierre P. ;Van Laethem, Jean-Luc
Référence Cancers, 15, 3, page (968)
Publication Publié, 2023-02-01
;Coulonval, Katia ;Raspé, Eric ;Demols, Anne ;Roger, Pierre P. ;Van Laethem, Jean-Luc Référence Cancers, 15, 3, page (968)
Publication Publié, 2023-02-01
Article révisé par les pairs
| Résumé : | Existing treatment strategies for pancreatobiliary malignancies are limited. Nowadays, surgery is the only path to cure these types of cancer, but only a small number of patients present with resectable tumors at the time of diagnosis. The notoriously poor prognosis, lack of diverse treatment options associated with pancreaticobiliary cancers, and their resistance to current therapies reflect the urge for the development of novel therapeutic targets. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have emerged as an attractive therapeutic strategy in a number of cancers since their approval for treatment in patients with ER+/HER- breast cancer in combination with antiestrogens. In this article, we discuss the therapeutic potential of CDK4/6 inhibitors in pancreatobiliary cancers, notably cholangiocarcinoma and pancreatic ductal adenocarcinoma. |
